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Abstract
Background—Mitochondria are key players in the development and progression of heart failure 
(HF). Mitochondrial (mt) dysfunction leads to diminished energy production and increased cell 
death contributing to the progression of left ventricular (LV) failure. The fundamental mechanisms 
that underlie mt dysfunction in HF have not been fully elucidated.
Methods and Results—To characterize mt morphology, biogenesis and genomic integrity in 
human HF, we investigated LV tissue from non-failing (NF) hearts and end-stage ischemic (ICM) 
or dilated (DCM) cardiomyopathic hearts. Although mt dysfunction was present in both types of 
cardiomyopathy, mt were smaller and increased in number in DCM compared to ICM or NF 
hearts. Mt volume density and mtDNA copy number was increased by ~2-fold (P<0.001) in DCM 
hearts in comparison to ICM hearts. These changes were accompanied by an increase in the 
expression of mtDNA-encoded genes in DCM versus no change in ICM. mtDNA repair and 
antioxidant genes were reduced in failing hearts suggestive of a defective repair and protection 
system, which may account for the 4.1-fold increase in mtDNA deletion mutations in DCM 
(P<0.05 vs NF hearts, P<0.05 vs ICM).
Conclusions—In DCM, mt dysfunction is associated with mtDNA damage and deletions, which 
could be a consequence of mutating stress coupled with a PGC-1α-dependent stimulus for mt 
biogenesis. However, this maladaptive compensatory response contributes to additional oxidative 
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damage. Thus, our findings support further investigations into novel mechanisms and therapeutic 
strategies for mt dysfunction in DCM.
Keywords
heart failure; mitochondrial biogenesis; mtDNA mutations; dilated cardiomyopathy; ischemic 
cardiomyopathy
Introduction
Mitochondria are the major site of energy production in the cell. Thus it is not surprising, 
that energy dependent tissues such as the heart are particularly sensitive to mt dysfunction. 
Accumulating evidence suggests that mt dysfunction reflected in the structure, function, and 
number of mitochondria within cardiac myocytes, leads to diminished energy production, 
loss of myocyte contractility, and increased cell death during the development of heart 
failure1, 2. However, despite extensive animal studies, the fundamental mechanisms behind 
mt dysfunction contributing to the development and progression of LV failure in humans 
have not been fully elucidated.
Each cardiac myocyte contains numerous mitochondria (50–100) and each mitochondria 
contains multiple copies of mtDNA (1–10 molecules/mitochondria)3. The abundance of 
mitochondria per cell is determined by the rate of mt biogenesis and cell division4. It has 
been reported that limited myocardial mt biogenesis occurs early in response to pathological 
stimuli but ultimately proliferation of mitochondria does not match the increased metabolic 
energy demand of the hypertrophied myocytes, which may contribute to the eventual 
decompensation of the heart5. The abundance of mitochondria per cell is tightly controlled 
by the activation of specific transcription factors and signaling pathways4, 6. Recent studies 
have revealed a central role of peroxisome proliferator-activated receptor γ coactivator 
(PGC)-1 alpha7 and c-Myc8 in mt biogenesis in the heart. Myc activation was shown to 
trigger mt biogenesis in adult heart by directly activating nuclear genes involved in mt 
replication and biogenesis, which was protective in response to ischemic stress8. 
Downregulation of PGC-1α and its target genes have been observed in number of rodent 
models of heart failure raising the intriguing possibility that impaired mt biogenesis can be a 
causal mechanism for mt dysfunction in HF9, 10. However, these models may not 
recapitulate the pathophysiology of human DCM. PGC-1α expression levels in human 
failing hearts has been more variable. Two studies examining the PGC-1α levels in human 
HF found a decrease in PGC-1α mRNA or protein levels11, 12. However, more recently it 
was reported PGC-1α protein levels are increased in failing human hearts. The difference in 
findings was attributed to the severity of HF as well as lack of age-matched control group 
used in previous studies13. All of these studies were done in cohorts of failing human hearts 
from mixed etiologies highlighting the need to further characterize mt biogenesis and related 
signaling pathways with respect to HF etiology.
Mt injury in failing heart can also be reflected by mtDNA damage, which is tightly 
associated with the expression of mt transcripts, proteins and mt function. Human mtDNA is 
a closed-circular, double-strand DNA molecule encompassing 16,569 bp and encoding 13 
Ahuja et al. Page 2
Circulation. Author manuscript; available in PMC 2014 November 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
proteins that are essential for mt biogenesis and respiratory function14. Human mtDNA is 
more susceptible to oxidative damage and consequently acquires mutations at a higher rate 
than nuclear DNA15, 16 due to exposure to high levels of free radicals and reactive oxygen 
species (ROS) generated during respiration, lack of protective histones and limited capacity 
for repair of mtDNA damage (for review, see17, 18). Thus, increased oxidative stress may 
contribute to alterations in the abundance of mitochondria as well as the copy number and 
integrity of mtDNA under pathological conditions. Indeed, increased oxidative stress may 
play a critical role in regulating the decline in mt abundance and mtDNA copy number in 
stressed cells16. When the capacity of the antioxidant system is compromised, higher 
oxidative stress results in an increase in defective mitochondria and mutated mtDNA leading 
to a cyclic increase in ROS production and further oxidative damage19. Despite strong 
evidence suggestive of abnormal mt biogenesis and increased mutated mtDNA copy number 
in aging tissues19, the relative importance of this process in HF, particularly with respect to 
different HF etiologies, is not known.
We have characterized the changes in mt morphological dynamics, biogenesis, mtDNA 
content and damage in subjects with HF of differing etiologies. We examined LV tissue 
from NF and from end-stage ICM and DCM human hearts. Mitochondria were fragmented 
and increased in number in DCM failing hearts compared to ICM and NF hearts. There was 
increased mtDNA copy number in DCM accompanied by an increase in the expression of 
mtDNA-encoded genes. In contrast, these parameters were reduced in failing ICM hearts 
consistent with published report. The stimulus for abnormal mt biogenesis in end-stage 
DCM hearts appeared to be PGC-1α dependent. Importantly, mt abnormalities in DCM 
were associated with a defective mtDNA repair system and increase in mtDNA deletion 
mutations. Taken together, these observations suggest that mt dysfunction in failing human 
hearts may be etiology specific. The basis for these differences is uncertain but raise hope 
that a better understanding of the pathophysiologic mechanisms could lead to novel 
therapies to prevent HF progression.
Methods
Myocardial Samples from NF and Failing Hearts
The failing heart samples (n=16) were obtained from the left ventricular (LV) anterior wall 
during heart transplantation or implantation of an LV assist device. The non-failing heart 
samples (NF) (n=8) were obtained from the LV free wall and procured from National 
Disease Research Interchange (NDRI) and University of Pennsylvania. NF heart donors had 
no history of macroscopic or laboratory signs of cardiac diseases. The tissue collection was 
approved by the UCLA Institutional Review Board #11-001053 and #12-000207.
Histochemistry
Hematoxylin and eosin (H&E) staining was performed according to the rapid H&E 
technique for cryostat sections20. Cytochrome c oxidase (COX) and succinate 
dehydrogenase (SDH) activity staining were performed as previously described21.
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Mitochondrial Electron Transport Chain Activity Assays
Mitochondrial Complex II activity was determined by standard spectrophotometric enzyme 
assay as described22. Activity of Complex II was measured by changes in absorbance at 600 
nm after reduction of artificial electron acceptor, 2,6-dichlorophenolindophenol (DCPIP). 
The absorbance at 600 nm was recorded continuously for 5 min. at every 30 sec. intervals. 
The relative Complex II activity was defined as the rate of change of absorbance per unit 
time of incubation.
Complex IV activity was measured using a microplate assay kit from Abcam according to 
the manufacturer’s procedure. Briefly, Complex IV was immunocaptured within the wells 
and activity was determined calorimetrically following the oxidation of reduced cytochrome 
c at 550 nm.
Transmission Electron Microscopy
Small pieces from the left myocardium were fixed in 2% glutaraldehyde, 2% 
paraformaldehyde at room temperature for 2h, followed by 24h at 4°C. Specimens were 
rinsed in 0.1 M phosphate buffer (PB), pH 7.4, fixed in 1% osmium tetroxide in PB (pH 7.4) 
at 4°C for 1h, dehydrated in graded ethanol followed by propylene oxide and embedded in 
Eponate 812 (TedPella Redding, CA). Ultra-thin sections (around 60–70 nm) from 
longitudinal parts were cut and contrasted with uranyl acetate followed by lead citrate and 
examined in a JEOL 10000X transmission electron microscope (Tokyo, Japan) at 80 kV.
Morphometric Analysis
Cardiac mt volume densities were determined from electron micrographs as described 
previously8. Data were expressed as volume density (volume of mitochondria [μm3] per 
cytoplasmic volume [μm3]).
Protein and RNA analysis
Western blots were performed on protein extracts from LV anterior wall samples, according 
to established protocols23. Total RNA was extracted from frozen tissue samples using Tri 
Reagent, Sigma and first strand cDNA were generated using Omniscript Reverse 
Transcriptase Kit (Qiagen) as per the manufacturer’s instructions. Primer sequences were 
designed with the OligoPerfect Designer software. Real-time quantitative PCR was 
conducted using ABI PRISM 7700 Sequence Detection System; (ABI, CA).
Oxyblot procedures
The Oxyblot Oxidized Protein Detection kit was purchased from Chemicon. Protein 
homogenates from LV anterior wall samples were derivatized with 1,3-
dinitrophenylhydrazine (DNPH) for 15 min according to the manufacturer’s instructions and 
followed by electrophoresis SDS-polyacrylamide gel.
Mitochondrial DNA copy measurement
DNA was collected from LV anterior wall from NF, DCM and ICM hearts. Real-time PCR 
was performed for cytochrome c oxidase subunit 1 (COX1) and peroxisome proliferative 
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activated receptor gamma coactivator-related (PPRC). Absolute COX1 DNA copies were 
normalized to a nuclear gene, PPRC1.
mtDNA Mutation Assays
The random mutation capture assays were performed as previously described21. Briefly, 
total DNA was digested with TaqI for 5 hr, with the addition of 100 units of TaqI every 
hour. DNA was then probed with primers flanking the TaqI restriction site in order to detect 
mtDNA genomes that contain a mutation in the TaqI restriction site. A second pair of 
primers was used to determine the amount of mtDNA genomes that was interrogated. The 
following primers were used for DNA amplification:
mtDNA control primer forward, ACAGTTTATGTAGCTTACCTCC;
mtDNA control primer reverse, TTGCTGCGTGCTTGATGCTTGT;
mtDNA deletion primer forward, GAACCAACACCTCTTTACAG;
mtDNA deletion primer reverse, CCTGCTAATGCTAGGCTGCC
Next generation sequencing was performed on Illumina GAIIx sequencer. Libraries of 
mtDNA were constructed according to the manufacturer’s instructions, and paired-end 
sequence reads of 75 nucleotides were obtained. To identify candidate deletions, each 
sequence read was trimmed to 70 nucleotides, and the 15 nucleotides at each end were 
mapped using Bowtie to the human mtDNA genome. Sequence reads with ends mapping to 
separate regions of the mtDNA genome were retrieved as candidate deletions. With this 
algorithm, deletions occurring within the central 40 nucleotide region of a sequence read 
could be identified. The candidate deletions were then manually verified. To minimize the 
false-positive rate, only deletions identified by four or more independent reads were 
included in the analysis.
SOD activity assay
To measure the MnSOD activity, mitochondria were isolated from frozen heart tissue using 
standard differential centrifugation in 10.0 mM Tris-HCl (pH 7.4), 10.0 mM Hepes, 250 
mM sucrose, 0.5 mM EGTA and 0.02% protease inhibitor cocktail24. MnSOD activity was 
measured using an assay kit from Abcam according to the manufacturer’s instruction. The 
data were presented as the percentage inhibition of the rate of superoxide anion generation 
from xanthine oxidase.
Statistical Analysis
All data are presented as mean ± SEM. Results were compared by one-way ANOVA using 
Fisher protected least significant difference tests as post-hoc corrections for multiple testing. 
Significance was declared at a P value less than 0.05. After statistical analysis, mRNA 
expression data of genes were grouped together based on functional similarity for 
presentation purposes.
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Results
Mitochondrial Functional Integrity and Respiratory Dysfunction in Failing Hearts
The characteristics of the subjects included in the ICM and DCM subgroups recorded at the 
time of sample collection are shown in Table 1. As a control, mRNA levels of brain 
natriuretic peptide (BNP) and alpha-myosin heavy chain (α-MHC) were determined by real-
time PCR in all samples (Suppl. Fig. 1). As expected, upregulation of BNP and 
downregulation of α-MHC were observed in failing hearts confirming integrity of samples 
(Suppl. Fig. 1A & B).
To determine the functional integrity of the mitochondria, end-stage DCM and ICM hearts 
were examined for activity of enzymes of the electron transport chain, SDH and COX (Fig. 
1A). Histological analysis revealed cardiac myocyte degeneration and cytoplasmic 
vacuolation in both ischemic and dilated cardiomyopathic hearts (Fig. 1A-b & c), which was 
associated with enlarged cross-sectional area of individual myocytes, particularly in DCM 
hearts (Fig. 1A-c). Histochemical staining for COX and SDH activities was performed to 
examine qualitative differences in these electron transport activities in ICM and DCM. This 
demonstrated decreased staining of COX (Fig. 1A e&f) and SDH in both ICM and DCM 
hearts (Fig. 1A-h & i) in comparison to NF hearts (Fig. 1A-d & g). To quantitate the 
observed decrease in electron transport chain activities, spectrophotometric enzyme assays 
was performed for complex IV and II on mt rich fractions isolated from NF, end-stage DCM 
and ICM hearts. As shown in Fig. 1 B&C, both ICM and DCM failing hearts demonstrated 
decrease in complex IV (Fig. 1B; P<0.05 vs NF hearts) and complex II (Fig. 1C; P<0.05 vs 
NF hearts) activities by almost 50% consistent with severe dysfunction of mt respiratory 
chain during HF in humans. The mt respiratory dysfunction in failing hearts prompted us to 
investigate whether increased levels of oxidation products could be detected in these failing 
human hearts. Analysis of protein oxidative stress was done by derivatizing carbonyl groups 
on oxidized proteins from NF and failing hearts with DNPH on oxyblot using 
immunoblotting. Representative example of oxyblot shown in Fig. 1D revealed increase in 
oxidized proteins in failing hearts.
Mitochondrial Morphology and Biogenesis in Failing Hearts
To determine whether mt morphology was also altered in end-stage human HF, electron 
microscopy was performed on myocardial sections from ICM (Fig. 2A-a) and DCM (Fig. 
2A-b) hearts. Mitochondria were more numerous but with abnormal morphology in DCM. 
The marked mt proliferation was accompanied by myofibrillar displacement and loss in 
DCM sections. Quantitative morphometric analysis confirmed a 2.2-fold increase in mt 
volume density in DCM hearts (Fig. 2B; P<0.001 vs ICM hearts). In contrast, electron 
micrographs of ICM myocardium depicted fewer mitochondria with fragmented 
morphology (Fig. 2A-a). To determine if the observed morphological changes in failing 
hearts was caused by an imbalance in mt dynamics, we analyzed total ventricular lysates 
from NF, ICM and DCM failing hearts for mt fusion and fission proteins. As shown in Fig. 
2C, mt fusion proteins such as MFN2, and OPA1 were increased in DCM hearts but 
decreased in ICM hearts. These observations suggest an imbalance in mt fusion and fission 
in end-stage HF.
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Since mt morphological and functional alterations are often associated with changes in 
mtDNA18, 25, we examined total mtDNA content. Total DNA (genomic and mtDNA) 
isolated from NF, ICM and DCM ventricles was assayed for levels of the mtDNA-encoded 
gene, COX1 and compared to the nuclear-encoded gene PPRC (Fig. 2D). The observed 
increase in mt number in DCM failing hearts was associated with a 2.41-fold increase in 
mtDNA (P<0.001 vs NF hearts). In contrast, ICM hearts displayed a 32% reduction in 
mtDNA content when compared to NF hearts (P<0.05). To rule out the possibility that the 
observed increased mtDNA was from a relative increase in the non-cardiac myocyte 
population in the failing hearts, expression levels of fibroblast marker DDR2 (Discoidin 
domain receptor 2) was determined from total ventricular RNA from NF, ICM and DCM 
hearts. There was no significant difference in expression of DDR2 in failing hearts when 
compared to NF hearts (Suppl. Fig. 2).
To investigate the basis for the mt dysfunction (Fig. 1) we assessed expression levels of a 
panel of genes encoded by mtDNA (Complex I genes ND1 and ND6) and nuclear DNA 
(nDNA) encoded genes (Complex II genes SDHA and SDHB) in failing hearts. As shown in 
Fig. 2E, DCM hearts demonstrated increased expression of both mtDNA encoded subunits 
ND1 and ND6 (Fig. 2E; 4.8 and 6.5-fold respectively; P<0.05 vs NF hearts), whereas ICM 
hearts had no significant change in expression of both mtDNA encoded genes (Fig. 2E). 
Interestingly, expression levels of nDNA encoded genes SDHA and SDHB were 
upregulated in both HF models compared to NF hearts (Fig. 2F). These changes in gene 
expression were associated with a corresponding increase in expression of mt encoded 
Complex I protein, ND1 and nuclear encoded Complex II protein, SDHA in DCM hearts 
(Fig 2G). Taken together, these results demonstrate that mtDNA content and mtDNA-
encoded genes are upregulated in DCM hearts and conversely, not significantly changed in 
ICM failing hearts.
Impaired Mitochondrial Biogenesis in Heart Failure
To determine the mechanisms underlying abnormal mt biogenesis in failing hearts, we 
evaluated the expression levels of key transcriptional regulators of mt biogenesis in heart, 
PGC-1α26 and c-Myc8 in NF, ICM and DCM hearts (Fig. 3 A & B). As shown in Fig. 3A, 
DCM hearts showed a 6-fold increase in protein levels (Fig. 3B; P<0.05 vs NF hearts) 
whereas protein levels of PGC-1α did not change significantly in ICM failing hearts. Protein 
levels of c-Myc were increased in both ICM and DCM (Fig. 3B), suggesting the important 
factor mediating the difference in mt biogenesis in the two etiologies was PGC-1α.
Since increased mt biogenesis in DCM failing hearts was associated with elevated levels of 
PGC-1α, we RNA for analyzed total ventricular downstream targets of PGC-1α such as 
nuclear respiratory factor 1 (NRF-1), mtDNA polymerase catalytic subunits POLG and 
POLG2 and mt transcription factor A (TFAM). As shown in Fig. 3C, there was a 4.9-fold 
increase in POLG (P<0.05), 3.25-fold (P<0.05) in POLG2 and 3.34-fold increase in TFAM 
(P<0.05) compared to NF hearts, while ICM hearts demonstrated no significant changes in 
the expression of these genes. These changes in expression of mt biogenesis regulatory 
genes were associated with a corresponding increase in protein expression of NRF-1, POLG 
and POLG2 in DCM hearts with no significant changes in ICM hearts when compared to NF 
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hearts (Fig. 3D). Thus, our results suggest that there is PGC-1α-associated abnormal mt 
biogenesis in DCM failing hearts in contrast to no significant change of mtDNA replication 
and biogenesis in ICM failing hearts.
Mitochondrial DNA Damage in Heart Failure
To determine if increase in mtDNA in DCM failing hearts is associated with mtDNA 
damage, we analysed mtDNA for deletion mutations. The prevalence of mtDNA deletions is 
inversely correlated with mt function in heart and skeletal muscle21. mtDNA deletion 
frequencies in the common deletion site in the major arc of the mt genome were determined 
using the random mutation capture (RMC) assay21. As shown in Fig. 4A, DCM failing 
hearts showed a 4.1-fold increase in frequency of mtDNA deletions (P<0.05 vs NF hearts). 
The trend for increased mtDNA deletions in ICM hearts was not significant when compared 
to NF hearts. To determine if the deletion mutations in DCM failing hearts were acquired 
during development of heart failure, we analyzed heart samples from DCM subjects who 
had been supported with left ventricular assist devices (LVAD) for an average of 2 months 
(Fig. 4A). LVAD support is associated with reverse remodeling and correction of mt defects 
in end-stage failing hearts (for review see27). mtDNA deletions were significantly reduced 
in LVAD-supported DCM hearts when compared to DCM failing hearts (Fig. 4A; P<0.05 vs 
DCM). These data suggest that deletion mutations observed in mtDNA of DCM failing 
hearts accumulate with the pathophysiologic signals in the failing ventricle.
To confirm and better characterize the increased mtDNA deletions in an unbiased manner, 
we performed next generation sequencing of mtDNA from NF and DCM failing hearts. For 
each sample, we obtained 5×105 to 1.1×106 mtDNA reads spanning 75 base pairs resulting 
in a 3,500–4,000-fold mt genome coverage. Both ends of each sequence read were mapped 
onto the mtDNA genome, and sequences with ends that mapped to different locations were 
identified as deletions. To minimize the chances of artifactual deletions, we only considered 
deletions that were identified by four or more independent sequence reads (Table 2). Two 
hundred and thirteen distinct deletions were identified by four or more independent 
sequence reads in DCM hearts representing deletions in 0.05% of the mt genomes. Although 
all DCM hearts exhibited mtDNA deletions, we observed deletions in only one NF heart 
representing a deletion rate of 0.003% in NF hearts (Table 2). Supplementary Fig. 3 depicts 
positions, sizes, frequencies and affected genes for each deletion for all 6 DCM subjects 
used in the study. We did not observe a correlation between the age of the subject and the 
frequency of mtDNA deletions; however the sample size was small and the stimulus for 
these mutations in failing myocardium may be much greater than that occurring with normal 
aging (Table 2). The histogram for one representative end-stage DCM failing heart is shown 
in Fig. 4B. It demonstrates that most of the mtDNA deletions were concentrated in the mt 
major arc. Fig. 4C is a schematic representation of the spectrum of deletion mutations 
observed in the same DCM failing heart demonstrating that most of the mtDNA deletion 
mutations were in the major arc of mt genome. These data suggest that the mt dysfunction is 
associated with mtDNA damage and deletions specifically in DCM hearts, which could be a 
consequence of mutating stress coupled with a PGC-1α-dependent stimulus for mt 
biogenesis.
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Mitochondrial DNA Repair in Failing Hearts
To evaluate the status of antioxidants and DNA repair mechanisms we examined ventricular 
RNA. Base excision repair (BER) genes such as human endonuclease III (NTHL11) and 8-
oxoG DNA glycosylase (OGG1) were upregulated in both HF etiologies. There was an 
increase in NTHL11 expression by 1.62 and 2.38-fold, and OGG1 by 2.75 and 5.3-fold in 
ICM and DCM hearts, respectively, (Fig. 5A; P<0.05 vs NF hearts). Expression levels of a 
panel of antioxidant genes such as manganese superoxide dismutase (SOD2), glutathione 
peroxidase-1 (GPX1), γ-glutamyl-cysteine synthetase light subunit (GCLM) and γ-glutamyl-
cysteine synthetase heavy subunit (GCLC) in failing hearts were also elevated. Significant 
increases in mRNA levels for SOD2 (2.83 and 3.64-fold), GPX1 (1.5 and 2.69-fold), GCLM 
(2.65 and 3.8-fold) and GCLC (2.74 and 5.2-fold) were found in ICM and DCM failing 
hearts (Fig. 5 C; P<0.05 vs NF hearts). A small, but significant increase in activity of 
MnSOD was also observed in mitochondria isolated from NF, ICM and DCM hearts (Fig. 
5D). Interestingly, despite elevations of BER gene expression, protein levels for NTHL1 
were reduced in failing hearts (Fig. 5B).
Discussion
Although the underlying injuries and stressors that lead to DCM or ICM are diverse, it has 
been assumed the pathophysiology, particularly with respect to cardiac mt dysfunction, is 
similar between these etiologies. This may be related to the fact that the mechanisms 
responsible for the mt dysfunction in human hearts are poorly understood and the animal 
models used to elucidate mechanisms may not reflect the true pathophysiology of human 
DCM. In the current study we performed a detailed morphological and molecular analysis of 
end-stage failing human hearts to characterize mt morphological integrity, proliferation, 
mtDNA content and damage in ICM and DCM. Our data demonstrates that DCM is 
associated with an increase in the number of fragmented mitochondria, mtDNA copy 
number and expression of mtDNA-encoded genes. In contrast, end-stage ICM hearts show a 
reduction in the number of mt, with corresponding decrease in mtDNA. This abnormal mt 
proliferation in DCM hearts appears to be PGC-1α-dependent and interestingly, is 
associated with an increase in mtDNA deletions. We speculate that this increase in mutated 
mtDNA in DCM hearts is a consequence of a stimulus for mt biogenesis in the setting of 
increased oxidative stress and a defective mtDNA repair system. Although certain 
limitations of the current study such as low sample size with a male predominance and 
increase in metabolic factors such as diabetes and hypertension in ICM, cannot be 
disregarded, however, this study was intended to be a pilot study to provide important 
insight into the mechanisms underlying human HF.
The electron transport chain (ETC) is an essential component of ATP production, and is 
embedded in the inner mt membrane. Defects in the individual complexes have been 
documented in HF (for review, see28). Decreased ETC enzyme activity occurs in all HF 
patients independent of the etiology29. Consistent with this, both DCM and ICM were 
associated with a decrease in activity of COX and SDH, subunits of Complex IV and II, 
respectively, indicative of mt respiratory chain dysfunction in HF, which was also 
corroborated with demonstration of increased oxidation of protein in these failing hearts. 
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The impairment of ETC was accompanied by defects in the mt dynamics in failing hearts. 
Although mt were more numerous with smaller and fragmented morphology in both DCM 
and ICM hearts suggesting a predominance of mt fission, in DCM there was concomitant mt 
biogenesis leading to an increase in total mt volume in contrast to ICM hearts, which 
displayed a significant reduction in mt volume. Defects in mt organization and the presence 
of abnormally small and fragmented mitochondria have been previously observed in end-
stage DCM, myocardial hibernation and ventricular associated congenital heart disease30. 
There was also an increase in mt fusion proteins such as OPA1 and MFN2 in DCM hearts; 
however, both were decreased in ICM hearts. Decreased protein levels of OPA1 have also 
been previously reported in human ICM, however, with increased MFN2. In contrast, in 
DCM OPA1 protein levels were unchanged, but MFN2 was increased31. The significance 
and contribution of abnormal mt dynamics in HF remains to be determined.
Alterations in intracellular levels of ROS are often associated with changes in mt abundance, 
mtDNA copy number and expression of respiratory genes (for review,16). Our data 
demonstrated increased mt proliferation in DCM hearts associated with increased mtDNA 
copy number and expression of mtDNA-encoded genes, while ICM hearts displayed a 
reduction in mtDNA. Our observations in ICM are similar to those made in mouse models 
of pathological remodeling after myocardial infarction, where the decline of mt function was 
associated with a reduction in mtDNA copy number32. Our findings in human DCM hearts 
parallel those reported in aging human tissues33, 34 and in response to DNA-damaging 
agents35 where increased mtDNA is associated with oxidative damage. The increase in mt 
mass and mtDNA in these studies has been proposed to be a compensatory mechanism 
against oxidative damage to mtDNA and respiratory chain components16. However, it 
should be noted that mtDNA estimations done in HF patients in the current study were 
compared with age matched NF hearts, thus implying, that age cannot account for the 
increase in mtDNA content in DCM hearts. Interestingly, Karamanlidis et al. recently 
showed a decrease in mtDNA, with an increase in PGC-1α, in failing hearts13. This 
unexpected finding might be due to use of ventricular samples from mixed etiology in their 
study. Our data from DCM hearts suggests that mt biogenesis was PGC-1α associated since 
Myc levels were similar in DCM and ICM and PGC-1α targets, NRF-1, mtDNA 
transcription factor, TFAM and mtDNA polymerase catalytic subunits POLG and POLG2 
required for mtDNA replication were induced in DCM. Thus, under oxidative stress, there is 
a coordinated nuclear and mt genome activation to induce mt biogenesis presumably to 
compensate for mt dysfunction. In skeletal muscle, mt proliferation has been shown to partly 
compensate for the respiratory dysfunction by maintaining overall ATP production36. 
However, in cardiac muscle, induction of mt biogenesis has been proposed to be a 
maladaptive response. In fact, cardiac-specific induction of PGC-1α in mice results in 
cardiac dysfunction with morphologic features of myocyte mt proliferation and myofibrillar 
disorganization and loss37.
In the current study, we found that mt respiratory dysfunction, abnormal mt proliferation and 
biogenesis in failing DCM hearts were associated with an increased frequency of mtDNA 
deletion mutations. Since the frequency of mtDNA deletions was found to be significantly 
reduced with LVAD-support in DCM failing hearts, this data suggests that the accumulation 
of mtDNA deletions are acquired during the development of heart failure as opposed to part 
Ahuja et al. Page 10
Circulation. Author manuscript; available in PMC 2014 November 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
of a more global mt syndrome. Although, the exact cause of accumulation of mtDNA 
deletions in DCM hearts is unknown, mtDNA deletion mutations and mt abnormalities have 
been previously described in idiopathic DCM in humans38, 39. It has been proposed, based 
on the size of mtDNA deletion mutations, that deletion-containing mt genomes have a 
replicative advantage40. Support for the replicative advantage of smaller genomes comes 
from re-population kinetic studies, where it was shown that partially deleted mtDNA 
molecules re-populate mitochondria faster than full-length genomes41. Although, the 
deletion mutation frequency observed in DCM failing hearts was quite low to affect the mt 
function, it is interesting to note that it has been shown that deletion mutations in cardiac 
myocytes accumulate clonally in aging heart42. mtDNA deletions were shown to accumulate 
to high fractions in certain cells within the cardiac tissue while most cells remain deletion 
free, which unfortunately could not be demonstrated in the our study as 4-fold mutation rate 
observed was in total ground up LV tissues. However, focal accumulation of mtDNA 
deletions beyond a certain threshold could lead to drop out of cardiac myocytes causing 
respiratory chain abnormalities and further production of free radicals exacerbating the HF 
syndrome. Whether the rates of mtDNA deletions we observed in DCM hearts have 
pathophysiologic consequences or are simply a marker for the enhance mtDNA synthesis 
remains to be determined. DCM is the most challenging form of heart failure, since it lacks 
any molecular diagnostic assays or effective therapies. In fact, accumulation of mtDNA 
deletions could potentially serve as a marker for the enhance mtDNA synthesis, 
mitochondrial genomic instability or mtDNA damage in DCM failing hearts and are areas of 
mitochondrial biology that should be looked in detail in future.
In our study, mtDNA damage in both models of HF was not associated with induction of 
antioxidant enzymes such as SOD2, GPX1 and GCL or BER enzymes, NTHL1 and OGG1, 
despite a marked up-regulation of these genes at the RNA level. Similar results have been 
previously reported in human HF43, leading us to speculate that end-stage HF is unable to 
respond to oxidative stress by adequately increasing the antioxidant response and mtDNA 
repair mechanisms. The best characterized DNA repair pathway in mitochondria has been 
BER44. However, accumulation of mtDNA deletions has been linked to decline in BER 
activities. The accumulation of mtDNA deletions in aging cells is associated with decreased 
mitochondrial BER glycosylases expression levels45. Additionally, mice deficient for 
NEIL1, a BER glyocsylase, accumulate mtDNA deletions compared to wild-type mice46, 
suggesting an important role of mitochondrial BER in prevention of mtDNA damage and 
deletions.
In summary, our findings suggest while HF of both etiologies is associated with mt 
dysfunction they exhibit divergent phenotypes with respect to mt biogenesis. DCM is 
associated with enhanced mt biogenesis and mtDNA deletions. mtDNA deletions can cause 
mt dysfunction, resulting in an inability of the heart muscle to maintain adequate energy 
production and continuing to cause oxidative stress. Although we cannot resolve whether the 
rate of mtDNA deletion we observed contributed to the mt dysfunction, it does suggest a 
unique pathophysiology for the development of DCM. A better understanding of 
mechanisms underlying human HF could lead to etiology specific therapies in HF, 
something that up to now has been lacking.
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SHORT COMMENTARY
Although the underlying injuries and stressors that lead to dilated cardiomyopathy 
(DCM) or ischemic cardiomyopathy (ICM) are diverse, it has been assumed the 
pathophysiology, particularly with respect to cardiac mitochondrial (mt) dysfunction, is 
similar between these etiologies. This may be related to the fact that the mechanisms 
responsible for the mt dysfunction in human hearts are poorly understood and the animal 
models used to elucidate mechanisms may not reflect the true pathophysiology of human 
DCM. In the current study we performed a detailed morphological and molecular 
analysis of end-stage failing human hearts to characterize mt morphological integrity, 
proliferation, mtDNA content and damage. Our data demonstrates that DCM is 
associated with an increase in the number of fragmented mitochondria, mtDNA copy 
number and expression of mtDNA-encoded genes. This abnormal mt proliferation in 
DCM hearts appears to be PGC-1α-dependent and interestingly, is associated with an 
increase in mtDNA deletions. We speculate that this increase in mutated mtDNA in 
DCM hearts is a consequence of a stimulus for mt biogenesis in the setting of increased 
oxidative stress and a defective mtDNA repair system.
In summary, our findings suggest DCM is associated with more mtDNA deletions than 
ICM, which can cause mt dysfunction, resulting in an inability of the heart muscle to 
maintain adequate energy production and continuing to cause oxidative stress. This 
suggests a unique pathophysiology for the development of DCM and thus a potential 
novel target for etiology specific therapies in HF, something that up to now has been 
lacking.
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Figure 1. Mitochondrial functional integrity and respiratory dysfunction in failing hearts
(A) H&E (a–c), COX (d–f) and SDH (g–i) stained frozen sections from NF, ICM and DCM 
left ventricular myocardium (n=3/group) showing cardiac myocyte degeneration and 
reduced functional state of electron transport chain complexes IV and II. Scale bar 
represents 50μm. Enzymatic activity of electron transport chain complexes (B) II and (C) IV 
on mt rich fractions obtained from NF, ICM and DCM hearts (*P<0.05 vs NF; n=8/group). 
(D) Representative micrograph of measurement of oxidized proteins in the failing hearts 
using oxyblot.
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Figure 2. Mitochondrial morphology and biogenesis in failing hearts
(A) Transmission electron microscopy performed on heart sections from (a) ICM and (b) 
DCM myocardium demonstrating abnormal mt biogenesis in failing hearts. Scale bar 
represents 1μm. (B) Quantitative morphometric measurement of mt cellular volume density 
(μm3/μm3) based on analysis of electron micrographs from ICM and DCM ventricles 
(*P<0.001 vs NF; n=4/group). (C) Total ventricular protein lysates from indicated 
phenotypes were probed with antibodies against mt fusion proteins (OPA1 and MFN2) 
along with GAPDH as a loading control (n=4/group). (D) Quantitative real-time PCR on the 
mt gene COX1, along with the nuclear gene PPRC as an internal control from NF, ICM and 
DCM hearts showing increase in mtDNA content in DCM hearts. (*P<0.001, **P<0.05 vs 
NF; n=8/group). (E) Quantification of mt encoded Complex I ND1 and ND6 genes on NF, 
ICM and DCM hearts. (n=8/group, *P<0.05 vs NF). (F) Quantification of nuclear encoded 
Complex II SDHA and SDHB genes on NF, ICM and DCM hearts. (*P<0.05 vs NF). (G) 
Total ventricular protein lysates from indicated phenotypes probed with antibodies against 
electron transport Complex I and II proteins (ND1 and SDHA) along with GAPDH as a 
loading control (n=4/group).
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Figure 3. Mitochondrial biogenesis in failing hearts
Total ventricular protein from NF, ICM and DCM ventricles assayed by (A) immunoblot 
and (B) quantified for mt biogenesis regulators PGC-1α and c-Myc. (*P<0.05 vs NF; (n=4/
group). (C) Real-time PCR from NF and failing ventricles for mt biogenesis genes POLG, 
POLG2 and TFAM. (*P<0.05, **P<0.05 vs NF; n=8/group). (D) Total ventricular lysates 
from NF, ICM and DCM probed with antibodies against NRF-1, POLG and POLG2 along 
with GAPDH as a loading control (n=4/group).
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Figure 4. Mitochondrial DNA deletion mutations in failing and in reverse remodeled hearts
(A) Deletions were PCR-amplified and quantified using RMC assay on DNA obtained from 
NF, ICM, DCM and Post-VAD supported hearts demonstrating increased frequency of 
mtDNA mutations in DCM hearts (*P<0.05, vs normal; n=8/group). (B) Histogram showing 
frequency of deletion mutations observed across the mt genome in one of the DCM failing 
heart. (C) Schematic representation of the human mtDNA-deletion mutations obtained from 
an end-stage DCM failing heart. mtDNA deletion mutations were determined by Solexa 
sequencing of mtDNA and breakpoints were determined by DNA sequence analysis. Arcs 
represent the deleted regions of the genome.
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Figure 5. Mitochondrial DNA repair in failing hearts
Total ventricular RNA (A) and protein (B) from NF, ICM and DCM ventricles assayed by 
real-time PCR and immunoblot for mt DNA repair genes NTHL1 and OGG1. (*P<0.05 vs 
NF; n=8/group). (C) Real-time PCR from NF and failing ventricles for mitochondrial anti-
oxidant genes SOD2, GPX1, GCLM and GCLC. (*P<0.05 vs NF; n=8/group. (D) Total 
ventricular protein lysates from NF, ICM and DCM determined for MnSOD activity (n=8/
group).
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Table 1
Preimplantation clinical characteristics of the patients.
NF HEART FAILURE
ICM DCM
NO. 8 8 8
Age in years, median (range) 55 (50–80) 53(40–60) 57(40–75)
Gender, male/female 4/4 6/2 6/2
Ejection Fraction, (%) 60±5* 20±5 20±5
Cardiac Index (L/min/m2) No Data 2.5±0.4 2.2±0.2
PWP, mm Hg No Data 20±5 27±5
Inotropic support, n - 5/8 7/8
Diabetic, n 0/4* 5/8 1/8
Renal disease, n 0/4* 1/8 3/8
Hypertension, n 0/4* 5/8 1/8
Smoking history, n 5/8* 1/8 0/8
*Clinical data for 4 out of 8 NF hearts.
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Table 2
Deletions of mtDNA found in NF and DCM patients by High-Throughput Sequencing.
Myocardial sample Age and sex of the patient #
 Distinct deletions Independent reads Deletion Frequency (%)
NF 1 54 M 90 448 0.01
NF 2 86 M n.d. n.d. n.d.
NF 3 84 M n.d. n.d. n.d.
DCM 24 31 M 73 353 0.03
DCM 33 63 M 11 45 0.01
DCM 28 74 M 55 246 0.02
DCM 15 62 M 61 265 0.03
DCM 46 49 M 4 16 0.003
DCM 44 51 M 9 132 0.2
#
Distinct deletions is column A, independent reads is sum of column E and deletion frequency is percentage of sum of column H over column I in 
Fig. S3.
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